Vivos Therapeutics 
The Patent Grant That Wasn't Enough
Vivos announced the grant of US Patent #12,697,190 on August 4, covering a vibrational oral appliance with mandibular advancement technology. The patent protects key intellectual property in the company's Vivos System, which treats obstructive sleep apnea, dentofacial abnormalities, and snoring through non-invasive dental appliances.
The market initially responded with enthusiasm. VVOS traded over 33 million shares on August 4 alone, compared to a float of approximately 3.19 million shares. This 10:1 volume-to-float ratio sent the stock briefly higher, closing up roughly 10% at $0.46. However, after-hours trading reversed the move, and premarket action on August 5 extended selling pressure to $0.32.
The sharp reversal illustrates a common microcap pattern: news catalysts trigger outsized volume spikes that rarely sustain. When the float is severely limited, even modest buying pressure creates large percentage moves that attract immediate profit-taking.
Dilution Concerns Compound the Selling Pressure
Beyond the technical spike dynamics, fundamental dilution concerns weighed heavily on VVOS. The company faces multiple concurrent share-creation mechanisms. An active rights offering allows existing holders to purchase additional shares at potentially discounted prices. Debt holders continue converting obligations into equity, adding float incrementally. Streeterville financing arrangements remain in place with an August 31 extension deadline, meaning additional share issuance appears imminent.
This combination of near-term dilution sources makes it difficult for buyers to establish long positions. Any stock appreciation simply creates an opportunity for existing stakeholders to exit or reduce exposure through secondary offerings or conversion windows.
CFO Transition: No Red Flags, But Uncertainty Remains
Vivos CFO Brad Amman resigned voluntarily on July 31, 2026, prompting speculation about management stability. The company appointed an external successor, stating no disagreements or concerns about financial reporting drove the transition. However, leadership changes in cash-burning microcaps often signal internal reassessments of burn rate and runway, adding a layer of uncertainty that traders priced into the stock during the selloff.
Earnings Ahead: Q2 Report Scheduled August 18
Vivos is not expected to report Q2 2026 results until August 18, 2026. Analysts project EPS of -$0.42 on revenue of $5.63 million. The patent grant provides no near-term revenue catalyst. The company posted Q1 2026 revenue of $5.14 million against operating expenses of $9.22 million, resulting in an operating loss of $6.62 million. Cash burn continues at a rate that will require additional financing within quarters.
The chart above shows VVOS declining from over $224 in late 2020 to under $0.32 today, illustrating the sustained downtrend that characterizes heavily diluted microcap stocks.
What Traders Should Watch Next
VVOS now sits near 52-week lows with a market cap of $1.88 million. Short interest of 1.2 million shares represents roughly 38% of the float, creating potential for a short squeeze if positive catalysts emerge. However, the dilution pipeline and cash burn trajectory argue against long-term positioning.
For traders watching VVOS, key watch points include the August 18 earnings release, any announcements regarding Streeterville financing resolutions, and unusual volume spikes that might indicate accumulation ahead of dilution windows. The patent grant itself adds long-term IP value but provides no immediate revenue impact for a company burning through roughly $6-7 million per quarter.
Monitor VVOS live quotes and set price alerts to track whether the stock stabilizes near current levels or extends the downtrend through the August 18 earnings report.